Goldman Sachs’s Tourmaline Bio TRML Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.87M | Buy |
179,721
+96,802
| +117% | +$1.55M | ﹤0.01% | 3186 |
|
|
2025
Q1 | $1.26M | Sell |
82,919
-22,210
| -21% | -$338K | ﹤0.01% | 3658 |
|
|
2024
Q4 | $2.13M | Buy |
105,129
+33,130
| +46% | +$672K | ﹤0.01% | 3434 |
|
|
2024
Q3 | $1.85M | Sell |
71,999
-35,409
| -33% | -$910K | ﹤0.01% | 3423 |
|
|
2024
Q2 | $1.38M | Sell |
107,408
-90,511
| -46% | -$1.16M | ﹤0.01% | 3427 |
|
|
2024
Q1 | $4.53M | Buy |
197,919
+188,916
| +2,098% | +$4.33M | ﹤0.01% | 2646 |
|
|
2023
Q4 | $236K | Buy |
9,003
+8,128
| +929% | +$213K | ﹤0.01% | 4270 |
|
|
2023
Q3 | $246K | Sell |
875
-1,045
| -54% | -$293K | ﹤0.01% | 4185 |
|
|
2023
Q2 | $58.4K | Sell |
1,920
-176
| -8% | -$5.35K | ﹤0.01% | 4655 |
|
|
2023
Q1 | $39.4K | Sell |
2,096
-1,892
| -47% | -$35.6K | ﹤0.01% | 4800 |
|
|
2022
Q4 | $40.7K | Buy |
3,988
+757
| +23% | +$7.72K | ﹤0.01% | 4813 |
|
|
2022
Q3 | $85K | Buy |
3,231
+788
| +32% | +$20.7K | ﹤0.01% | 4957 |
|
|
2022
Q2 | $110K | Sell |
2,443
-39
| -2% | -$1.76K | ﹤0.01% | 5081 |
|
|
2022
Q1 | $244K | Buy |
2,482
+173
| +7% | +$17K | ﹤0.01% | 4988 |
|
|
2021
Q4 | $353K | Buy |
+2,309
| New | +$353K | ﹤0.01% | 4706 |
|